0001209191-22-062627.txt : 20221223
0001209191-22-062627.hdr.sgml : 20221223
20221223164730
ACCESSION NUMBER: 0001209191-22-062627
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20221221
FILED AS OF DATE: 20221223
DATE AS OF CHANGE: 20221223
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: RENSCHLER MARKUS MD
CENTRAL INDEX KEY: 0001217598
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40499
FILM NUMBER: 221485899
MAIL ADDRESS:
STREET 1: C/O PHARMACYCLICS INC
STREET 2: 995 E ARQUES AVE
CITY: SUNNYVALE
STATE: CA
ZIP: 94085-4521
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cyteir Therapeutics, Inc.
CENTRAL INDEX KEY: 0001662244
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 455429901
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SPRING STREET
STREET 2: BUILDING A, SUITE 510
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 857-285-4140
MAIL ADDRESS:
STREET 1: 128 SPRING STREET
STREET 2: BUILDING A, SUITE 510
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-12-21
0
0001662244
Cyteir Therapeutics, Inc.
CYT
0001217598
RENSCHLER MARKUS MD
C/O CYTEIR THERAPEUTICS, INC.
128 SPRING ST, BUILDING A, SUITE 510
LEXINGTON
MA
02421
1
1
0
0
President and CEO
Common Stock
2022-12-21
4
M
0
106345
1.03
A
948299
D
Common Stock
2022-12-21
4
M
0
30437
1.20
A
978736
D
Stock Option (Right to Buy)
1.03
2022-12-21
4
M
0
106345
0.00
D
2028-12-10
Common Stock
106345
0
D
Stock Option (Right to Buy)
1.20
2022-12-21
4
M
0
30437
0.00
D
2030-02-24
Common Stock
30437
32973
D
Due to rounding in connection with the Issuer's reverse stock split during its initial public offering, the exercise price and the number of securities underlying this option were immaterially incorrect as reported on the Reporting Person's Form 3 filing on June 17, 2021. These numbers have been corrected in this Form 4.
The option vested at a rate of 18,334 shares per month at the end of each successive one-month period beginning January 3, 2019, for 40 months, and at a rate of 14,703 shares per month at the end of the 41st month, at which point the option was fully vested.
The option vests as to 1/48th of the underlying shares of common stock on February 1, 2020, and at the same rate at the end of each successive one-month period following such date until the fourth anniversary of such date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
Exhibit List: Exhibit 24 - Power of Attorney
/s/ Adam M. Veness, as attorney-in-fact for Markus Renschler, M.D.
2022-12-23
EX-24
2
poa.txt
POA DOCUMENT
SUBSTITUTE POWER OF ATTORNEY
Pursuant to the Limited Power of Attorney of Markus Renschler (the "Power of
Attorney"), dated May 21, 2021 and filed with the Securities and Exchange
Commission, the undersigned has been constituted and appointed true and lawful
attorney-in-fact, with full power of substitution, to, on behalf of Dr.
Renschler:
(1) prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID,
including amendments thereto, and any other documents necessary or appropriate
to obtain codes and passwords enabling the undersigned to make electronic
filings with the SEC of reports required by Section 16(a) of the Securities
Exchange Act of 1934, as amended, or any rule or regulation of the SEC;
(2) execute for and on behalf of the undersigned, in the undersigned's capacity
as officer and/or director of Cyteir Therapeutics, Inc. (the "Company"), Forms
3, 4, 5 and any Schedules 13D or 13G in accordance with Section 16(a) of the
Securities Exchange Act of 1934, as amended, and the rules thereunder;
(3) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to complete and execute any such Form 3, 4, or 5
or Schedule 13D or 13G, complete and execute any amendment or amendments
thereto, and timely file such form with the SEC and any stock exchange or
similar authority; and
(4) take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of each such attorney-in-fact, may be of benefit
to, in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by each such attorney-in-fact on behalf
of the undersigned pursuant to this Power of Attorney shall be in such form and
shall contain such terms and conditions as each such attorney-in-fact may
approve in each such attorney-in-fact's discretion.
Pursuant to the powers granted to the undersigned in the Power of Attorney, the
undersigned hereby constitutes and appoints Adam Veness as a substitute to the
undersigned attorney-in-fact, with full power of substitution, and with full
power and authority to do and perform every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of the rights and powers granted
to the undersigned in said Power of Attorney. For the avoidance of doubt, the
foregoing appointment shall not serve as a revocation of the powers granted to
the undersigned himself in the Power of Attorney.
This Substitute Power of Attorney shall remain in full force and effect unless
and until revoked by the undersigned.
[Remainder of page intentionally left blank]
IN WITNESS WHEREOF, the undersigned has caused this Substitute Power of
Attorney to be executed as of this 23rd day of December, 2022.
/s/ David Gaiero
-------------------
David Gaiero